阐明间充质癌细胞状态中的暗激酶。

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-03-03 DOI:10.1158/2159-8290.CD-24-1884

Shensi Shen, Zhen Tan

引用次数: 0

摘要

Killarney及其同事发现PKN2是通过YAP/TAZ激活间充质癌细胞存活和耐药的关键驱动因素。靶向PKN2联合一线靶向治疗提供了一种消除间充质样耐药持久性细胞的潜在策略。参见基拉尼等人的相关文章，第595页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Illuminating a Dark Kinase in the Mesenchymal Cancer Cell State.

Killarney and colleagues identify PKN2 as a critical driver of mesenchymal cancer cell survival and drug resistance through YAP/TAZ activation. Targeting PKN2 in combination with first-line targeted therapies offers a potential strategy to eliminate mesenchymal-like drug-tolerant persister cells. See related article by Killarney et al., p. 595.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.